Orally Active Purine-Based Inhibitors of the Heat Shock Protein 90
- 24 December 2005
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (2) , 817-828
- https://doi.org/10.1021/jm0503087
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Novel, Potent Small-Molecule Inhibitors of the Molecular Chaperone Hsp90 Discovered through Structure-Based DesignJournal of Medicinal Chemistry, 2005
- Design, Synthesis, and Evaluation of a Radicicol and Geldanamycin Chimera, RadamideOrganic Letters, 2004
- Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenograftsCancer Chemotherapy and Pharmacology, 2004
- Targeting Wide-Range Oncogenic Transformation via PU24FCl, a Specific Inhibitor of Tumor Hsp90Chemistry & Biology, 2004
- Altered states: selectively drugging the Hsp90 cancer chaperoneTrends in Molecular Medicine, 2004
- Adenine derived inhibitors of the molecular chaperone HSP90—SAR explained through multiple X-ray structuresBioorganic & Medicinal Chemistry Letters, 2003
- A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitorsNature, 2003
- Synthesis and Antitumor Activity of Novel O-Carbamoylmethyloxime Derivatives of RadicicolJournal of Medicinal Chemistry, 2003
- BCR-ABL point mutants isolated from patients with imatinib mesylate–resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90Blood, 2002
- Development of a Purine-Scaffold Novel Class of Hsp90 Binders that Inhibit the Proliferation of Cancer Cells and Induce the Degradation of Her2 Tyrosine KinaseBioorganic & Medicinal Chemistry, 2002